Integrative echocardiographic assessment of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair.
MitraClip
echocardiography
mitral valve
secondary mitral regurgitation
transcatheter mitral valve repair
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
received:
07
02
2021
accepted:
31
07
2021
pubmed:
19
8
2021
medline:
6
1
2022
entrez:
18
8
2021
Statut:
ppublish
Résumé
To investigate whether the integrative echocardiographic criteria used in the cardiovascular outcomes assessment of the mitraclip percutaneous therapy (COAPT) for heart failure patients with functional mitral regurgitation study predict outcomes after edge-to-edge trancatheter mitral valve repair (TMVr) for the treatment of secondary mitral regurgitation (SMR). Two randomized controlled trials comparing TMVr to medical treatment reported conflicting findings. Differences in patient selection criteria may have contributed to these diverging results. Patients undergoing TMVr were stratified following the integrative COAPT echocardiographic criteria in noneligible and eligible patients who were further classified into three tiers according to effective regurgitant orifice (EROA) (Tier 1: EROA ≥ 0.3cm Between March 2011 and March 2018, 138 patients (mean age 75 years) satisfying the inclusion criteria underwent TMVr for treatment of symptomatic SMR. The mean EROA area was 0.35 ± 0.17 mm SMR patients stratified into tiers according to the COAPT integrative echocardiographic criteria have diverging prognostic and symptomatic benefit after edge-to-edge TMVr.
Sections du résumé
OBJECTIVES
To investigate whether the integrative echocardiographic criteria used in the cardiovascular outcomes assessment of the mitraclip percutaneous therapy (COAPT) for heart failure patients with functional mitral regurgitation study predict outcomes after edge-to-edge trancatheter mitral valve repair (TMVr) for the treatment of secondary mitral regurgitation (SMR).
BACKGROUND
Two randomized controlled trials comparing TMVr to medical treatment reported conflicting findings. Differences in patient selection criteria may have contributed to these diverging results.
METHODS
Patients undergoing TMVr were stratified following the integrative COAPT echocardiographic criteria in noneligible and eligible patients who were further classified into three tiers according to effective regurgitant orifice (EROA) (Tier 1: EROA ≥ 0.3cm
RESULTS
Between March 2011 and March 2018, 138 patients (mean age 75 years) satisfying the inclusion criteria underwent TMVr for treatment of symptomatic SMR. The mean EROA area was 0.35 ± 0.17 mm
CONCLUSIONS
SMR patients stratified into tiers according to the COAPT integrative echocardiographic criteria have diverging prognostic and symptomatic benefit after edge-to-edge TMVr.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1404-1412Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Varadarajan P, Sharma S, Heywood JT, Pai RG. High prevalence of clinically silent severe mitral regurgitation in patients with heart failure: role for echocardiography. J Am Soc Echocardiogr. 2006;19(12):1458-1461.
Bursi F, Barbieri A, Grigioni F, et al. Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study. Eur J Heart Fail. 2010;12(4):382-388.
Goliasch G, Bartko PE, Pavo N, et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J. 2018;39(1):39-46.
Dziadzko V, Clavel MA, Dziadzko M, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018;391(10124):960-969.
Swaans MJ, Bakker AL, Alipour A, et al. Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients. JACC Cardiovasc Interv. 2014;7(8):875-881.
Giannini C, Fiorelli F, De Carlo M, et al. Comparison of percutaneous mitral valve repair versus conservative treatment in severe functional mitral regurgitation. Am J Cardiol. 2016;117(2):271-277.
Praz F, Grasso C, Taramasso M, et al. Mitral regurgitation in heart failure: time for a rethink. Eur Heart J. 2019;40:2189-2193.
Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging. 2018;12(2):353-362.
Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379(24):2307-2318.
Iung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail. 2019;21:1619-1627.
Asch FM, Grayburn PA, Siegel RJ, et al. Echocardiographic outcomes after Transcatheter leaflet approximation in patients with secondary mitral regurgitation: the COAPT trial. J Am Coll Cardiol. 2019;74:2969-2979.
Lancellotti P, Moura L, Pierard LA, et al. European Association of E. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11(4):307-332.
Lancellotti P, Tribouilloy C, Hagendorff A, et al. Scientific document Committee of the European Association of cardiovascular I. recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14(7):611-644.
Zoghbi WA, Enriquez-Sarano M, Foster E, et al. American Society of E. recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16(7):777-802.
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native Valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30(4):303-371.
Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 2000;21(16):1387-1396.
Packer M, Grayburn PA. New evidence supporting a novel conceptual framework for distinguishing proportionate and disproportionate functional mitral regurgitation. JAMA Cardiol. 2020;5:469-475.
Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379(24):2297-2306.
Adamo M, Cani DS, Gavazzoni M, et al. Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair. EuroIntervention. 2020;16:413-420.
Topilsky Y, Inojosa JM, Benfari G, et al. Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction. Eur Heart J. 2018;39(39):3584-3592.
Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. 2019;140(3):196-206.
Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74(24):2998-3008.
Tang GHL, Verma S, Bhatt DL. Two randomized clinical trials on the treatment of secondary mitral regurgitation-contradictory or complementary? JAMA Cardiol. 2019;4(4):311-313.
Orban M, Hausleiter J. Transcatheter treatment of functional mitral regurgitation after MITRA-FR and COAPT - patient selection is most important. Int J Cardiol. 2019;288:57-58.
Pibarot P, Delgado V, Bax JJ. MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results. Eur Heart J Cardiovasc Imaging. 2019;20(6):620-624.
Senni M, Adamo M, Metra M, Alfieri O, Vahanian A. Treatment of functional mitral regurgitation in chronic heart failure: can we get a 'proof of concept' from the MITRA-FR and COAPT trials? Eur J Heart Fail. 2019;21(7):852-861.
Grayburn PA, Carabello B, Hung J, et al. Defining "severe" secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol. 2014;64(25):2792-2801.
Bartko PE, Arfsten H, Heitzinger G, et al. A unifying concept for the quantitative assessment of secondary mitral regurgitation. J Am Coll Cardiol. 2019;73(20):2506-2517.
Orban M, Karam N, Lubos E, et al. Impact of proportionality of secondary mitral regurgitation on outcome after Transcatheter mitral valve repair. JACC Cardiovasc Imaging. 2021;14(4):715-725.
Brugger N, Seiler C. Proportionality of functional mitral regurgitation: questioning the Model's fundamentals and its applicability in clinical practice. JACC Cardiovasc Imaging. 2020;13(6):1456-1457.
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-2791.